MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Maze Therapeutics, Inc. following a significant stock price decline after the announcement of clinical trial results [1][4]. Group 1: Investigation Details - The investigation focuses on whether Maze's executive officers may have violated federal securities laws, potentially allowing for recovery of investor losses [1][4]. - Investors who purchased Maze securities and suffered losses are encouraged to join the investigation, with no cost or obligation [2]. Group 2: Clinical Trial Results - On March 25, 2026, Maze announced topline results from its Phase 2 HORIZON trial for MZE829, reporting a mean reduction in urine albumin-to-creatinine ratio (uACR) of approximately 35.6% at Week 12, with about 50% of patients achieving over a 30% reduction [3]. - The company characterized these results as "clinically meaningful" and indicative of initial clinical proof-of-concept [3]. Group 3: Stock Price Reaction - Following the announcement of the clinical trial results, Maze's stock price declined by approximately 33% on the same day [4].